<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Human leucocyte antigen (HLA) expression is altered in oesophageal <z:mp ids='MP_0002038'>carcinomas</z:mp> compared with <z:mpath ids='MPATH_458'>normal</z:mpath> tissue </plain></SENT>
<SENT sid="1" pm="."><plain>It is unclear, however, whether this phenotype precedes <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> or results as a consequence of it </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To investigate HLA class I and II expression in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> squamous oesophageal tissue </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Asian patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (n = 64) and a control group (n = 60) with a <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus but without reflux symptoms were recruited using endoscopic and histopathological criteria </plain></SENT>
<SENT sid="4" pm="."><plain>Tissue samples were stained with monoclonal antibodies specific for HLA-ABC, HLA-DR alpha chain or HLA-DP/DQ/DR, and scored semiquantitatively </plain></SENT>
<SENT sid="5" pm="."><plain>The results of immunohistochemical staining were correlated with clinical and histopathological characteristics of patients </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Marked expression of HLA-ABC was observed in 50% of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> sections as compared with 68.3% of controls (p = 0.038) </plain></SENT>
<SENT sid="7" pm="."><plain>HLA-DR staining was seen in 51.6% of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> samples versus 11.7% of controls (p&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Expression of HLA-DP/DQ/DR was evident in 73.4% of oesophageal <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> tissue as opposed to 18.3% of controls (p&lt;0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Importantly, a total loss of HLA-ABC and a concomitant gain of HLA-DP/DQ/DR expression were seen in 37.5% of patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> but in none of the controls (p&lt;0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>Interestingly, this phenotype was associated positively with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (adjusted p, p* = 0.031) but negatively with <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drug</z:chebi> use (p* = 0.004) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: HLA class I expression is down regulated and class II expression is up regulated in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>As these changes predate <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e>, altered major histocompatibility complex expression may be a key event in disease progression, possibly in facilitating evasion from immune surveillance </plain></SENT>
</text></document>